FAST Conference Draws 20 Pharmaceutical Companies and Raises Over $2.2 Million for Research
Downers Grove, IL – December 7, 2020 – The Foundation for Angelman Syndrome Therapeutics (FAST) today announced that Virtually Unstoppable, their annual
Frequently asked questions regarding the GeneTx KIK-AS Clinical Trial
GeneTx Biotherapeutics has announced it has received IRB approval from Rush University Medical Center in Chicago, IL to begin the «KIK-AS» (Knockdown of UB
A message to the Angelman community from GeneTx Biotherapeutics
Two press releases were issued recently with one announcing an Exclusive Option Agreement between GeneTx Biotherapeutics, LLC («GeneTx») and Ultragenyx
Angelman Biomarkers and Outcome Measures Alliance and Roche begin patient-centered qualitative research to inform potential outcome measures for Angelman syndrome clinical trials
F. Hoffmann-La Roche Ltd, (Roche), one of the world’s largest pharmaceutical and diagnostics companies, announced today that it has funded the first phase
Ganaxalone As Potential Therapeutic For Angelman Syndrome
[wpv-autop]Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model.[/wpv-autop][wpv-
FAST US and FAST AU Announce Joint Funding To Dr. Arthur Beaudet To Generate Mouse Lines Expressing Human UBE3A Antisense
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (
FAST Summit Live stream
Watch all the news and updates from the Science Summit 9-5pm Friday, December 2 (CST) and
the Education Summit on Saturday December 3, 9-4PM.
Maggie Linton Show
Dr Allyson Berent, the Chief Science Officer at the Foundation for Angelman Syndrome Therapeutics, talks with popular radio journalist Maggie Linton about An
FDA Grants Orphan Drug Designation to Gene Therapy Treatment for Angelman Syndrome
Agilis Biotherapeutics and Dr. Edwin Weeber take giant step forward toward a functional cure for Angelman Syndrome. For Further information, read the press
Ovid Therapeutics Launches First Sponsored Clinical Trial For Angelman Syndrome
Ovid Therapeutics announces the first ever sponsored clinical trial for Angelman Syndrome. You first heard about Gabaxadol from Dr. Matthew During at the FAS